Drug Trial Radar · NCT01631266
Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI
Last checked: Nov 19, 2026Latest source record: Apr 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
979
Actual
Start
Jul 2012
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Statens Serum InstitutAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 6 weeks, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Tuberculosis (TB) continues to be the most important bacterial infection worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. We are investigating a new skin test named C-Tb. Like the current tuberculin skin test (PPD), the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions. The aim of this trial is to test the C-Tb skin test in volunteers. The volunteers are divided into four groups: * Negative control group: Must have no history of exposure to a person with tuberculosis disease. * Occasional contact: Must be in contact with a person with tuberculosis disease between 6 hours/week and 6 hours/day * Close contact: Must be in close contact with a person with tuberculosis disease for more than 6 hours/day for at least five days * Positive control group: Must have a confirmed tuberculosis disease within the last 3 years. The goals of this clinical trial are: * To compare the C-Tb test to a blood test, the QuantiFERON test. * To compare the C-Tb test to the PPD test that is currently being used. * To assess the safety of the C-Tb test.
Conditions
- Tuberculosis
Interventions
C-TbBiological
The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
2 T.U. Tuberculin PPD RT 23 SSIBiological
The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate an increasing trend in C-Tb test positivity across the four study groups, with 'positivity' defined as an induration ≥ 5 mmTime frame: Onset between the injections and 28 days after the injections
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario de Cruces
Barakaldo, Basque Country, Spain
CAP Drassanes, Unitat de Prevenció i Control de Tuberculosi
Barcelona, Catalonia, Spain
Hospital del Mar
Barcelona, Catalonia, Spain
Public Health Agency of Barcelona
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Hospital Vall d'Hebron
Barcelona, Catalonia, Spain
Hospital Clínic i Provincial de Barcelona
Barcelona, Catalonia, Spain
Hospital Mutua de Terrassa
Barcelona, Catalonia, Spain
Hospital San Joan De Deu
Barcelona, Catalonia, Spain
Hospital Universitario Lucus Augusti
Lugo, Galicia, Spain
Complexo Hospitalario de Pontevedra
Pontevedra, Galicia, Spain
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, Galicia, Spain
Complexo Hospitalario Universitario de Vigo
Vigo, Galicia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.